Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2007

Upstream Retains Genpathway to Advance Oncology Biomarker Studies

  • Genpathway will help Upstream Biosciences validate its prostate and liver cancer biomarkers and drug response assay.
    Upstream has identified specific genetic variations to use as diagnostic biomarkers for various forms of cancer.

    Genpathway will use its ChIP assays to provide information for the next phase of the company’s program. The assays will help elucidate parameters involving specific gene transcription factors and pathways.

    "This agreement with Genpathway,” notes Upstream CEO Joel Bellenson, “builds on the important analytic work we already have under way with NimbleGen and may allow us to acquire in-depth information that is not available with other analytic methods."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »